Uterine serous papillary carcinomas overexpress human trophoblast-cell- surface marker (trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-trop-2 monoclonal antibody

Cancer

Volumn 117, Issue 14, 2011, Pages 3163-3172

  Varughese, Joyce ^a   Cocco, Emiliano ^a   Bellone, Stefania ^a   De Leon, Maria ^a   Bellone, Marta ^a   Todeschini, Paola ^b   Schwartz, Peter E ^a   Rutherford, Thomas J ^a   Pecorelli, Sergio ^b   Santin, Alessandro D ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

antibody dependent cellular cytotoxicity; endometrial neoplasms; hRS7; Trop 2; trophoblast cell surface marker; uterine serous papillary carcinoma

Indexed keywords

CELL MARKER; IMMUNOGLOBULIN G; INTERLEUKIN 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HRS7; RITUXIMAB; TROPHOBLAST PROTEIN 2; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENTIATION; DRUG SENSITIVITY; ENDOMETRIUM CELL; FEMALE; FLOW CYTOMETRY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; NATURAL KILLER CELL; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UTERINE SEROUS PAPILLARY CARCINOMA; UTERUS CARCINOMA;

ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, NEOPLASM; CARCINOMA, PAPILLARY; CELL ADHESION MOLECULES; CELL LINE, TUMOR; FEMALE; HUMANS; INTERLEUKIN-2; UTERINE NEOPLASMS;

EID: 79960024794     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25891     Document Type: Article

References (33)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60: 277-300.
2. Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R,. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol. 1982; 6: 93-108. (Pubitemid 12108965)
3. Creasman W, Kohler M, Odicino F, et al. Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium. Gynecol Oncol. 2004; 95: 593-596. (Pubitemid 39610410)
4. Schwartz PE,. The management of serous papillary uterine cancer. Schwartz PE. Curr Opin Oncol. 2006; 18: 494-499. (Pubitemid 44199847)
5. Carcangiu ML, Chambers JT,. Uterine papillary serous carcinoma: a study on 108 cases with emphasis on prognostic significance of associated endometrioid carcinoma, absence of invasion, and concomitant ovarian cancer. Gynecol Oncol. 1992; 47: 298-305. (Pubitemid 23011408)
6. Goff BA, Kato D, Schmidt RA, et al. Uterine papillary serous carcinoma: pattern of metastatic spread. Gynecol Oncol. 1994; 54: 264-268. (Pubitemid 24301898)
7. Hecht JL, Mutter GL,. Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol. 2006; 24: 4783-4791. (Pubitemid 46630943)
8. Santin AD, Bellone S, Van Stedum S, et al. Determination of HER-2/neu status in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry and fluorescence in situ hybridization. Gynecol Oncol. 2005; 98: 24-30. (Pubitemid 40826414)
9. Santin AD, Bellone S, Van Stedum S, et al. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma. Cancer. 2005; 104: 1391-1397. (Pubitemid 41356154)
10. Santin AD, Zhan F, Cane′ S, et al. Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy. Br J Cancer. 2005; 92: 1561-1573. (Pubitemid 40705026)
11. Lipinski M, Parks DR, Rouse RV, Herzenberg LA,. Human trophoblast cell-surface antigens defined by monoclonal antibodies. Proc Natl Acad Sci U S A. 1981; 78: 5147-5150. (Pubitemid 12229690)
12. Miotti S, Canevari S, Ménard S, et al. Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. Int J Cancer. 1987; 15: 297-303. (Pubitemid 17038183)
13. Alberti S, Miotti S, Stella M, et al. Biochemical characterization of Trop-2, a cell surface molecule expressed by human carcinomas: formal proof that the monoclonal antibodies T16 and MOv-16 recognize Trop-2. Hybridoma. 1992; 50: 1330-1336.
14. Nakashima K, Shimada H, Ochai T, et al. Serological identification of Trop-2 by recombinant cDNA expression cloning using sera of patients with esophageal squamous cell carcinoma. Int J Cancer. 2004; 112: 1029-1035. (Pubitemid 39507010)
15. Zhang L, Zhou W, Velculescu VE, et al. Gene expression profiles in normal and cancer cells. Science. 1997; 276: 1268-1272. (Pubitemid 27227367)
16. Mühlmann G, Spizzo G, Gostner J, et al. TROP2 expression as prognostic marker for gastric carcinoma. J Clin Pathol. 2009; 62: 152-158.
17. Fong D, Moser P, Krammel C, et al. High expression of TROP2 correlates with poor prognosis in pancreatic cancer. Br J Cancer. 2008; 99: 1290-1295.
18. Fong D, Spizzo G, Gostner JM, et al. TROP2: a novel prognostic marker in squamous cell carcinoma of the oral cavity. Mod Pathol. 2008; 21: 186-191. (Pubitemid 351172170)
19. Fang YJ, Lu ZH, Wang GQ, et al. Elevated expressions of MMP7, TROP2, and survivin are associated with survival, disease recurrence, and liver metastasis of colon cancer. Int J Colorectal Dis. 2009; 24: 875-884.
20. Bignotti E, Todeschini P, Calza S, et al. Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. Eur J Cancer. 2010; 46: 944-953.
21. Stein R, Basu A, Chen S, Shih LB, Goldenberg DM,. Specificity and properties of MAb RS7-3G11 and the antigen defined by this pancarcinoma monoclonal antibody. Int J Cancer. 1993; 55: 938-946. (Pubitemid 24005338)
22. Stein R, Govindan SV, Mattes MJ, et al. Targeting human cancer xenografts with monoclonal antibodies labeled using radioiodinated, diethylenetriaminepentaacetic acid-appended peptides. Clin Cancer Res. 1999; 5 (suppl): 3079s-3087s. (Pubitemid 29493899)
23. Govindan SV, Stein R, Qu Z, et al. Preclinical therapy of breast cancer with a radioiodinated humanized anti-EGP-1 monoclonal antibody: advantage of a residualizing iodine radiolabel. Breast Cancer Res Treat. 2004; 84: 173-182. (Pubitemid 38393367)
24. El-Sahwi K, Bellone S, Cocco E, Cargnelutti M,. al. In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma. Br J Cancer. 2010; 102: 134-143.
25. Cubas R, Li M, Chen C, Yao Q,. Trop2: a possible therapeutic target for late stage epithelial carcinomas. Biochim Biophys Acta. 2009; 1796: 309-314.
26. Guerra E, Trerotola M, Dell', Arciprete R, et al. A bicistronic CYCLIN D1-TROP2 mRNA chimera demonstrates a novel oncogenic mechanism in human cancer. Cancer Res. 2008; 68: 8113-8121.
27. Wang J, Day R, Dong Y, Weintraub SJ, Michel L,. Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancers. Mol Cancer Ther. 2008; 7: 280-285. (Pubitemid 351302522)
28. Cross SN, Cocco E, Bellone S, et al. Differential sensitivity to platinum-based chemotherapy in primary uterine serous papillary carcinoma cell lines with high vs low HER-2/neu expression in vitro. Am J Obstet Gynecol. 2010; 203: 162. e1-e8.
29. Caron PC, Lai LT, Scheinberg DA,. Interleukin-2 enhancement of cytotoxicity by humanized monoclonal antibody M195 (anti-CD33) in myelogenous leukemia. Clin Cancer Res. 1995; 1: 63-70.
30. Caligiuri MA, Murray C, Robertson MJ, et al. Selective modulation of human natural killer cells in vivo following prolonged infusion of low-doses recombinant interleuikin 2. J Clin Invest. 1993; 91: 123-128.
31. Ortaldo JR, Woodhouse CS, Morgan AC Jr, Herberman RB, Cheresh DA, Reisfeld RA,. Analysis of effector cells in human antibody-dependent cellular cytotoxicity with murine monoclonal antibodies. J Immunol. 1987; 138: 3566-3572. (Pubitemid 17071947)
32. Villella JA, Cohen S, Smith DH, Hibshoosh H, Hershman D,. HER-2/Neu overexpression in uterine papillary serous cancers and its possible therapeutic implications. Int J Gynecol Cancer. 2006; 16: 1897-1902. (Pubitemid 44470053)
33. Santin AD, Bellone S, Roman JJ, McKenney JK, Pecorelli S,. Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu. Int J Gynecol Obstet. 2008; 102: 128-131.